Envestnet Asset Management Inc. Has $5.55 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Envestnet Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,614 shares of the biotechnology company's stock after purchasing an additional 4,847 shares during the period. Envestnet Asset Management Inc.'s holdings in Sarepta Therapeutics were worth $5,546,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. World Investment Advisors LLC acquired a new stake in Sarepta Therapeutics during the third quarter worth about $2,418,000. Tidal Investments LLC raised its position in shares of Sarepta Therapeutics by 91.2% during the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock worth $704,000 after purchasing an additional 2,688 shares during the period. Garden State Investment Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $2,115,000. GAMMA Investing LLC lifted its holdings in shares of Sarepta Therapeutics by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 185 shares during the last quarter. Finally, Everence Capital Management Inc. acquired a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $344,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of recent research reports. Royal Bank of Canada cut Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their target price for the company from $161.00 to $87.00 in a research note on Monday, March 31st. Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research note on Thursday, April 3rd. Scotiabank decreased their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. HC Wainwright reiterated a "neutral" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Finally, Wells Fargo & Company began coverage on Sarepta Therapeutics in a research report on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Trading Down 2.1 %

Shares of NASDAQ:SRPT traded down $1.32 during midday trading on Friday, reaching $60.44. The company had a trading volume of 1,312,734 shares, compared to its average volume of 1,424,339. The company has a fifty day simple moving average of $77.32 and a two-hundred day simple moving average of $105.79. The firm has a market cap of $5.86 billion, a price-to-earnings ratio of 48.35 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 1-year low of $48.01 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.